Overview

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This study aims to provide essential mechanistic insights into natriuretic and hemodynamic effects of SGLT2i and GLP-1RA agents in T2D patients. Ultimately, by obtaining physiological data in T2D patients without HF, our aims are to gain insight into how the use of this combined therapy may be used in T2D with HF in future work.

Phase:

Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Empagliflozin
Liraglutide